Blurb
Dangote Cement is creating its own luck
Not only was the company able to basically eliminate Nigeria’s dependence on imported cement, but it also made Nigeria an exporter of cement to other neighbouring nations.
The year 2020 came with good tidings for Dangote Cement Plc. Beyond commissioning its Onne Export Terminal in Port Harcourt and its gas power plant in Tanzania, the group bagged over a trillion in revenue—a 16% jump from its N892 billion turnover in the year 2019. The company also successfully carried out a bond issuance and buyback programme while increasing its capacity by 3 million tonnes in Nigeria. Group sales volumes were up by 8.6% to 25.7 million tonnes across both cement and clinker lines, and finance income increased by 292% to about N30 billion, culminating in a profit before tax of N373 billion. Not bad at all for a pandemic-stricken year. Interestingly, most of these didn’t come by chance; the company appears to be creating its own luck.
READ: Dangote Cement considers debt funding options under 300 billion bond issuance programme
Here’s how:
Tighter Costs
It is not uncommon to see companies significantly increase their administrative or marketing costs in a bid to attain higher turnover. If it is because they believe that there is a direct correlation between how much is spent on overheads or marketing and the increase in revenue, Dangote Cement has certainly proven them wrong. Administrative costs for the year 2020 remained comparatively the same as its 2019 figure and selling and distribution expenses were even marginally lower despite its higher revenue. Hence, despite the circa 49% increase in taxes from its previous year disbursement, Dangote Cement still attained a profit of N276 billion for the year—38% higher than the previous year.
READ: Aliko Dangote’s net worth falls by $1.4 billion in Q1 2021 amid stock market sell-off
Increased investments (& Liabilities)
While it is true that you need to spend money to make money, expenses don’t do much when it comes to growth—investments are what make all the difference. Dangote Cement currently has its operations in Cameroon (1.5Mta clinker grinding), Congo (1.5Mta), Ghana (1.5Mta import), Ethiopia (2.5Mta), South Africa (2.8Mta), Tanzania (3.0Mta), and Zambia (1.5Mta), amongst others. In addition to its 32.25Mta production capacity in Nigeria, it now boasts a total of 48.6Mta capacity across Africa.
Not only was the company able to basically eliminate Nigeria’s dependence on imported cement, but it also made Nigeria an exporter of cement to other neighbouring nations. Its financials reveal a 15% increase in PPE to N1.4 trillion, also leading to a proportionate increase of 16% with N2 trillion in total assets. The downside? A 34% increase in total liabilities to also over a trillion, with both current and non-current liabilities increasing from prior year figures. With the higher demand for cement following recovery infrastructure spending, demand for more concrete roads, and increasing real estate development projects, its investments and industry monopoly will, however, place it in one of the best positions it can be. Consequently, it still has some of the best long-term credit ratings globally—and expectedly so.
READ: Dangote Cement pays N1.1 trillion in dividends in 5 years.
Investor Focused
The Chief Executive Officer, Michel Puchercos, in his notes on the results, revealed that Dangote Cement experienced its strongest year in terms of EBITDA and volumes; he also attributed a lot of it to their increased focus in protecting their people, customers, and communities particularly from the impact of the pandemic. Earnings per share, as noted in the results, was up 36.9% to ₦16.14 and proposed dividend was maintained at ₦16.00 per share. The company has paid more dividends to shareholders in the last five years than any other company on the NSE. However, with its cement rumoured to be one of the most expensive globally, offering value to its investors is certainly the least it can do.
Blurb
Dangote Sugar records revenue boost despite inflation and Apapa gridlock
Dangote Sugar has revealed it increased prices in the first quarter of 2021 to mitigate the problems of rising inflation and depreciation.
One of Nigeria’s largest Sugar manufacturers, Dangote Sugar revealed it increased prices in the first quarter of 2021 to mitigate the problems of rising inflation and depreciation.
In a note to investors, the company revealed its recent 41.5% surge in revenues was due to an increase in sales volume as well as an uptick in price. In the first quarter of 2021, Dangote Sugar posted a revenue of N67.39 billion compared to N47.6 billion, the same period in 2020. The increase in price was driven by 5.7% pop in sales volume as the company sold 200,510 tonnes of sugar in the quarter compared to 189, 724 the same period in 2020.
But while sales value surged by 41.5%, volumes only rose 5.7% suggesting that price increase was a catalyst for the growth in revenue and the company alluded to this in its statement.
READ: Dangote set to earn N13 billion in dividend from his sugar business
Dangote Sugar’s performance
“Group sales volume increased in the quarter by 5.7% to 200,510 tonnes (2020: 189,724 tonnes). Growth continued to benefit from the sustained efforts to drive customer base expansion, several trade initiatives and investments. Group production volume also increased by 4.3% to 200,783 tonnes (2020: 192,584 tonnes) due to our operations optimization strategy despite the challenges of the Apapa traffic situation. Group revenue increased by 41.5% to N67.39 billion (2020: N47.64 billion). Growth in revenue advanced ahead of volume growth due to pricing benefits. Gross profit increased by 41.8% to N18.04 billion (2020: N12.72 billion) on account of better topline performance. EBITDA increased by 34.7% to N17.02 billion (2020: N12.64 billion) on account of increased earnings. Group profit after taxation for the period increased by 30.3% to N8.30 billion (2020: N6.37 billion) reflecting management’s unrelenting drive to deliver consistent shareholder value.”
The company also explained it had no choice but to increase prices because of the impact of the 2020 devaluation, higher inflationary environment, port congestion issues and a rise in global sugar prices. The company imports raw sugar from Brazil, under the government’s backward integration plan.
“We have continued to witness high cost of raw materials, energy costs and other input costs due to rising inflation and FX rate fluctuation. Further cost escalation is anticipated in the year as inflationary pressure mounts,” the company said.
READ: Dangote Sugar yearly revenue surge by 33%, announces a dividend of N1.50
Dangote vs BUA Sugar Scarcity Controversy
Just last month, the company’s adversary and competitor BUA Group accused Dangote Sugar of conniving with Flour Mills of Nigeria (FMN) in price-fixing and arbitrary collusion to create sugar scarcity and keep the price of the commodity high.
This triggered Dangote Sugar and FMN into issuing a joint press statement denying the accusations.
The allegation made by BUA was triggered by a joint letter written by John Coumantaros of FMN Plc and Aliko Dangote of Dangote Industries Limited, reporting key developments in the Nigerian Sugar Industry to the Minister of Industry Trade and Investment, Niyi Adebayo.
The duo in the letter dated January 28, 2021, pointed out how BUA’s new sugar refinery in Port Harcourt may lead to a spike above the import quota as stipulated in the National Sugar Master Plan (NSMP), and how BUA’s investment in the sugar industry via the new refinery is non-compliant to the undertakings under its Backward Integration Programme, in line with local production.
READ: Dangote’s stakes in his sugar enterprise has earned him N90 billion in 365 days
BUA’s response however led to an immediate reply by the duo of Dangote Sugar and Flour Mills of Nigeria.
“In line with this, the Dangote Sugar Refinery wishes to vehemently refute the allegations and assertions made by BUA Sugar Refinery as they are not only false but defamatory, malicious and libellous, as they were geared at tarnishing the good name and brand of Dangote Sugar Refinery Plc and Dangote Industries Limited.”
The Group Managing Director, Mr Ravindra Singhvi, explained that the Dangote Group is socially responsible and considers price-fixing to be unethical and disastrous to the nation’s economy, and as such, the allegations made by BUA is highly mischievous and defamatory and should be considered a malicious attempt to smear the reputation of DSR.
“DSR does not engage in artificial price manipulation of its products, either during the Holy month of Ramadan or at any other time. We have never ever increased the price of our food items or commodities during the Holy month of Ramadan in the history of our operations,” Ravindra Singhvi said.
Outlook for Dangote Sugar
Despite the operational headwinds, the company insist it is on track to improve its operations and seek growth in its sugar sales volumes. It also recently received approval from the government to revise its local sugar production targets to 550,000 metric tonnes annually from over 1 million metric tonnes annually.
“Despite these uncertainties, achievement of our Sugar for Nigeria Backward Integration Project goal remains a key priority, though we anticipate increase in cost to completion in Naira-terms and some delays in Letter of Credit establishment for the importation of plant and equipment. The focus is to achieve the Federal Government’s revised sugar production target of 550,000 metric tonnes annually by 2024. We remain confident of the huge benefits the Backward Integration Programme would deliver and the positive impacts it will have on the economy.”
Find out why Dangote Sugar is recommended as a buy in our Stock Select Portfolio Newsletter? Click here.
Blurb
GlaxoSmithKline in big trouble as losses mount
The results were less than impressive with several key indicators showing a year-on-year decline.
GlaxoSmithKline Consumer Nigeria Plc (“GSK Plc” or “the Company”) is a public limited liability company with 46.4% of the shares of the Company held by Setfirst Limited and Smithkline Beecham Limited (both incorporated in the United Kingdom), and 53.6% held by Nigerian shareholders.
The ultimate parent and controlling party is GlaxoSmithKline Plc, United Kingdom (GSK Plc UK). The parent company controls GSK Plc through Setfirst Limited and SmithKline Beecham Limited.
The Company recently published its unaudited first quarter (Q1) 2021 consolidated financial statements for the period ended 31 March 2021.
READ: GSK Consumer Nigeria Plc records 3.34% increase in 2020 9M revenues
The results were less than impressive with several key indicators showing a year-on-year decline. For example, Group revenue (turnover) declined from ₦4.99 billion in Q1 2020 to ₦3.46 billion in Q1 2021 a drop of over 30.66%. The revenue drop was due to a sharp decline in the local sale of its healthcare products.
Total loss after tax as of Q1 2021 was ₦238.07 million compared to a profit after tax of ₦113.47 million for the same period to Q1 2020.
The company is essentially divided into two segments viz: Consumer Healthcare and Pharmaceuticals. While the Healthcare segment was largely profitable in Q1 2021 (making a profit before tax of ₦ 8.73 million by March 31, 2021, the pharmaceuticals segment made a loss of ₦262.93 million in the same period.
READ: GlaxoSmithKline Nigeria announces changes in its board
The Consumer Healthcare segment of the company consists of oral health products, digestive health products, respiratory health products, pain relievers, over the counter medicines, and nutritional healthcare; while the pharmaceutical segment consists of antibacterial medicines, vaccines, and prescription drugs. While goods for the consumer healthcare segment are produced in the country, the pharmaceuticals are all imported.
The largely imported pharmaceutical products are thus exposed to the vagaries of foreign currency fluctuations coupled with a negligible to no revenue from the foreign sale of its healthcare products (same as in Q1 2020) as it barely exports its products out of the country.
The cost of importing the antibacterial, vaccines and prescription drugs, and the significant local operating expenses wiped off the marginal gross profits made by the pharmaceutical segment of the company. In effect, the gross profit of ₦508.12 million made by the pharmaceutical segment of the company was eliminated by an operating expense of ₦735.7 million and this resulted in a net loss for the pharmaceutical segment of the business.
READ: Nigerian Breweries posts N7.66bn as Q1 2021 profit, shares gain 2.2%
Apart from the impact of imported pharmaceutical products as already discussed, other issues that affected the company’s Q1 2021 results and are likely to continue to affect its performance in future include:
- A limited product mix that has only the likes of Macleans and Sensodyne (Oral Healthcare); Pain relievers (Panadol and Voltaren); Digestive Health (Andrews Liver Salt); and Respiratory Health (Otrivin and Panadol Cold and Catarrh) all within the Consumer Healthcare segment.
- Increased competition, particularly from local pharmaceutical manufactures of similar over the counter medicines and other prescription medications and vaccines.
In addition, in October 2016, GSK Plc divested its drinks bottling and distribution business that manufactures and distributes Lucozade and Ribena in Nigeria, and other assets including the factory used for the drinks business to Suntory Beverage & Food Limited. The loss in revenue from these popular brands continues to impact its topline.
GlaxoSmithKline (GSK) is a global healthcare company and is well-known and acknowledged for its pioneering role in discovering and distributing vaccines for the likes of hepatitis A and B, meningitis, tetanus, influenza, rabies, typhoid, chickenpox, diphtheria, whooping cough, cervical cancer and many more.
It is also renowned for its manufacture and distribution of prescription medicines such as antibiotics and treatments for such ailments as asthma, HIV/AIDS, malaria, depression, migraines, diabetes, heart failure, and digestive disorders.
Perhaps GSK Plc’s fortunes may change if the company is able to obtain the parent company’s licence to manufacture GSK-owned vaccines and prescription medicines within the country while also exploring the possibility of extending the sale of its products outside the shores of the country.
Since different expertise is required for vaccines and prescription drug manufacture and distribution as compared to manufacture and sale of consumer healthcare products, perhaps another alternative may be for the company to create two separate companies with one company being a 100% vaccines and prescription drug pharmaceutical manufacturing and distribution company while the second company specializes entirely in the manufacture and sale of consumer healthcare products.
As a result of the Q1 2021 performance, the company’s earnings per share (EPS) dropped to -20 kobo compared to the 9 kobo earnings per share reported in Q1 2020. At the start of 2021, GSK Plc’s share price was ₦6.90 but the company has since lost over 10% of its price valuation as the company’s share price closed at ₦6.20 on April 30, 2021.
1 Comment